NCT07139535View on ClinicalTrials.gov

A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

350

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2026

Conditions

T2DM

Interventions

DRUG

RAY1225

Administered SC

DRUG

placebo

Administered SC

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijingcun

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY